A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
To investigate the dose response in respect of weight decrease following repeated oral
administration of OPC-131461 at 1, 2, 5, and 10 mg or placebo in patients with CHF with
volume overload despite having received diuretics other than vasopressin antagonists